Goserelin 3.6 MG

DRUG6 trials

Sponsors

Peking University People's Hospital, International Cancer Research Group, United Arab Emirates, National Taiwan University Hospital, Bradley Nindl, Xijing Hospital

Conditions

Breast CancerBreast Neoplasm FemaleHER2 Negative Breast CancerHypogonadismMusculoskeletal InjuryProstate Cancer

Phase 2

Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

RecruitingNCT06575257

Xijing HospitalProstate Cancer

Start: 2024-05-01End: 2029-05-31Target: 80Updated: 2024-08-28

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

RecruitingNCT06953882

Yale UniversityHER2 Negative Breast Cancer

Start: 2025-07-09End: 2030-09-30Target: 140Updated: 2025-07-14

Phase 3

Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

CompletedNCT03447132

International Cancer Research Group, United Arab EmiratesBreast Neoplasm Female

Start: 2017-12-20End: 2021-07-20Updated: 2023-03-10

Phase 4

Adaptions and Resiliency to Multi-Stressor OpeRations

RecruitingNCT06455969

Bradley NindlHypogonadism, Musculoskeletal Injury

Start: 2024-07-15End: 2026-08-01Target: 120Updated: 2025-08-24

Unknown Phase

Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients

Active, not recruitingNCT02430103

Peking University People's HospitalBreast Cancer

Start: 2015-12-25End: 2024-12-31Updated: 2024-12-12

Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer

RecruitingNCT04894188

National Taiwan University HospitalProstate Cancer

Start: 2022-01-27End: 2041-07-01Target: 38Updated: 2022-04-07

Related Papers

Abstract PS5-09-06: A Phase II Adjuvant Trial Evaluating the Impact of Omitting Chemotherapy Based on Patient's Selection for Moderate to High-Anatomical Risk, Low-Genomic Risk, ER-positive, HER2-negative Breast Cancer with a Combination Regimen of Ribociclib and Optimized Endocrine Therapy - SELECT Trial

Clinical Cancer Research2026-02-17

Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial.

2023-01-2112 citations

Final result for SAFIA trial for neoadjuvant palbociclib in patients with operable luminal breast cancer responding to fulvestrant.

Journal of Clinical Oncology2022-06-014 citations

Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China

Human Reproduction2020-12-0515 citations

A multicentre, international neoadjuvant, double-blind, randomized phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib (CDK 4/6 inhibitor) in patients with operable luminal breast cancer responding to fulvestrant (SAFIA study)

Annals of Oncology2018-10-01